Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

CAR T Cell Therapy Companies

ID: MRFR/HC/6630-CR
200 Pages
Vikita Thakur
Last Updated: February 16, 2025
CAR-T cell therapy (Chimeric Antigen Receptor T-cell therapy) is an innovative approach in cancer treatment, where a patient's T-cells are genetically engineered to target and destroy cancer cells. Several companies are at the forefront of CAR-T cell therapy development and commercialization.
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

CAR T Cell Therapy Market
Market Size
Forecast Period2026 - 2035
CAGR (2026 - 2035)15.48%
2025 Market Size$ 5.7 Billion
2026 Market Size$ 7.2 Billion
2035 Market Size$ 62.2 Billion
Key Players
Companies such as Gilead Sciences
Novartis
Bristol-Myers Squibb
Celgene
Amgen
Janssen Pharmaceuticals
Opportunities
  • Rising Incidence of Cancer
  • Growing Awareness and Acceptance
  • Regulatory Support and Approvals

Top Industry Leaders in the CAR T Cell Therapy Market

CAR-T Cell Therapy Key Companies*Disclaimer: List of key companies in no particular orderLatest CAR-T cell therapy Companies Update
  • Bluebird Bio (US)
  • Intellia Therapeutics (US)
  • Noile-Immune Biotech (Japan)
  • Celgene Corporation (US)
  • Bellicum Pharmaceuticals, Inc. (US)
  • Novartis International AG (Swiss)
  • Celyad (Belgium)
  • Cellectis (France)
  • Servier Laboratories (France)
  • Pfizer Inc. (US)
  • Caribou Biosciences, Inc. (US)
  • Mereck KGaA (Germany)
  • Amgen Inc. (US)